IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
74 hedge funds and large institutions have $245M invested in IGM Biosciences in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 15 closing their positions.
999% more call options, than puts
Call options by funds: $912K | Put options by funds: $83K
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
0.43% less ownership
Funds ownership: 61.69% → 61.26% (-0.43%)
10% less funds holding
Funds holding: 82 → 74 (-8)
20% less capital invested
Capital invested by funds: $305M → $245M (-$59.6M)
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.02M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.68M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.24M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.72M |
| 2 |
Alkeon Capital Management
New York
|
-$2.51M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.77M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$1.53M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.39M |
IGMS Hedge Fund Activity: Q1 2023 in Review
74 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2023, worth a combined $245M — down 20% from $305M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of IGMS and 7 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 28 added.
The largest buyer was Goldman Sachs, adding an estimated $4.02M. The largest seller was Millennium Management, cutting an estimated $5.72M.
- 74 institutional investors held IGM Biosciences (IGMS) as of Q1 2023, down from 82 in Q4 2022.
- Funds reported $245M of IGM Biosciences stock for Q1 2023, down 20% quarter-over-quarter.
- 7 funds opened new IGM Biosciences positions in Q1 2023 and 15 closed out, a net change of -8 holders.
- The largest IGM Biosciences buyer in Q1 2023 was Goldman Sachs, an estimated $4.02M added.
- The largest IGM Biosciences seller in Q1 2023 was Millennium Management, an estimated $5.72M sold.
Based on aggregated 13F filings for Q1 2023.